CORRECTION -- Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2023 20:30 ET
|
Day One Biopharmaceuticals, Inc.
BRISBANE, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), please note that in the second...
Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2023 17:00 ET
|
Day One Biopharmaceuticals, Inc.
New clinical data from registrational FIREFLY-1 study to be featured as an oral presentation Conference call and webcast scheduled on Sunday, June 4, 2023 at 6:00 p.m. CT BRISBANE, Calif., May 25,...
Day One Reports First Quarter 2023 Financial Results and Corporate Progress
May 01, 2023 09:00 ET
|
Day One Biopharmaceuticals, Inc.
FIREFLY-1 clinical abstract selected for oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Leadership team strengthened with executive appointments in clinical...
Day One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
April 26, 2023 09:31 ET
|
Day One Biopharmaceuticals, Inc.
New clinical data from registrational FIREFLY-1 study to be featured as an oral presentation Trial-in-progress poster from FIREFLY-2 and healthcare resource use for pediatric low-grade glioma care...
Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress
April 12, 2023 08:00 ET
|
Day One Biopharmaceuticals, Inc.
BRISBANE, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted...
Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress
March 06, 2023 16:30 ET
|
Day One Biopharmaceuticals, Inc.
First patient dosed in pivotal Phase 3 FIREFLY-2/LOGGIC trial evaluating tovorafenib (DAY101) as a frontline therapy for patients newly diagnosed with pediatric low-grade glioma (pLGG) Reported...
Day One to Participate in the Cowen 43rd Annual Health Care Conference
February 27, 2023 08:00 ET
|
Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
Day One Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade Glioma
January 08, 2023 17:00 ET
|
Day One Biopharmaceuticals, Inc.
Overall response rate (ORR) of 64% and clinical benefit rate (CBR) of 91% in 69 heavily-pretreated, RANO-evaluable patientsMedian duration of 8.4 months on therapy as of September 28, 2022, with 77%...
Day One to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 20, 2022 08:00 ET
|
Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
Day One to Participate in the Piper Sandler 34th Annual Healthcare Conference
November 17, 2022 07:00 ET
|
Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...